J&J expects to file for approval of 11 drugs by 2015

05/26/2011 | Wall Street Journal, The · Reuters

Johnson & Johnson intends to submit 11 treatments for regulatory approval by 2015, the health care giant told analysts and investors. Among them are Alzheimer's disease medicine bapineuzumab and type 2 diabetes drug canagliflozin. "We are returning to growth, and we expect to outpace market growth," said Sheri McCoy, vice chairwoman and executive-committee member.

View Full Article in:

Wall Street Journal, The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC